Skip to content

Hyun Kyu Min

3 papers in the library · 4 citations · publishing 2021-2023

Papers

Sort Most recent Most cited

Abused drug-induced intracranial self-stimulation is correlated with the alteration of dopamine transporter availability in the medial prefrontal cortex and nucleus accumbens of mice.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie November 8, 2023 Yong-Qing Zhang, Hyun Kyu Min, Eunchong Hong et al.

Intracranial self-stimulation (ICSS) of the medial forebrain bundle in mice is an experimental model use to assess the relative potential of reward-seeking behaviors. Here, we used the ICSS model to evaluate the abuse potential of 18 abused drugs: 3-Fluoroethamphetamine (3-FEA); methylphenidate; cocaine; dextroamphetamine; alpha-Pyrrolidinobutyrophenone (α-PBT); 4'-Fluoro-4-methylaminorex...

Rewarding and reinforcing effects of two dissociative-based new psychoactive substances, deschloroketamine and diphenidine, in mice.

Pharmacology, Biochemistry, and Behavior February 1, 2022 Jin Mook Kim, Boreum Han, Hyun Kyu Min et al. 4 citations

Dissociative-based new psychoactive substances (NPSs) are increasingly available through the Internet, and public health problems related to the recreational use of these substances have been increasing globally. Two such NPSs are deschloroketamine and diphenidine, which are primarily used recreationally as ketamine substitutes. However, there is little scientific evidence to describe the...

DOI: 10.1016/j.pbb.2022.173333 (opens in new tab) Full text (opens in new tab) Conditioned place preference Dependence liability Deschloroketamine Diphenidine +2

Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.

Archives of Pharmacal Research April 2021 Eun Yong Chung, Hye Jin Cha, Hyun Kyu Min et al.

Over the last decade, new psychoactive substances (NPS) have continuously been the focus of the international society since their emergence on the illicit drug market. NPS can be classified into six groups including; synthetic cannabinoid receptor agonists (SCRAs), stimulants, opioids, dissociatives, sedatives/hypnotics, and classic hallucinogens with psychoactive effects. These are sold as...

DOI: 10.1007/s12272-021-01326-6 (opens in new tab) Full text (opens in new tab) Adverse effects New psychoactive substances Pharmacology Toxicity